Clinical Trial Update: Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab with paclitaxel, with or without bevacizumab, for recurrent triple-negative breast cancer; recruitment is ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• KEYTRUDA (PEMBROLIZUMAB)
• Taxol (paclitaxel)

Snippet

Sponsor: Yukinori Ozaki | Conditions: Recurrent Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING